SAHPRA GMP Compliance: Addressing Allegations A...

By HEOR Staff Writer

February 25, 2026

SAHPRA GMP compliance at Adcock Ingram's Clayville facility has been reaffirmed by the South African Health Products Regulatory Authority (SAHPRA) in its
Economic Impact of Industry Clinical Trials in Europe
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Executive Director Recruitment: Leading the Future of Medicines Regulation
Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...